Broadening the possibilities of blood purification
CytoSorbents’ technology represents an advanced approach to hemoadsorption — and it all starts with a bead. All our solutions are based on a proprietary, biocompatible, and highly porous polymer bead platform, designed to adsorb selected substances from whole blood that, at excessive levels, may be harmful to the body.
The power of bead technology checked
CytoSorbents’ advanced bead technology – based on beads no larger than grains of salt – is ISO 10993 certified for biocompatibility and hemocompatibility.
Targeted and selective
Only small and middle-sized molecules—up to approximately 60 kDa — can enter the inner porous structure of the polymer beads. This size selectivity excludes larger plasma proteins such as albumin, coagulation factors, and immunoglobulins from relevant adsorption.
Adsorption of hydrophobic substances
Adsorption refers to the attachment of molecules onto a surface through physico-chemical interactions, whereas processes such as dialysis rely on diffusion or convection. Molecules with hydrophobic structural characteristics — such as certain cytokines and antithrombotic agents — can bind to the polymer surface and become captured within the bead’s porous matrix.
Biocompatibility
The device materials have been designed to minimize blood cell interaction and complement activation during use.
Concentration-Dependent Adsorption
Substances at higher concentrations are preferentially adsorbed by the polymer beads, whereas compounds at lower concentrations are removed more slowly. This concentration-dependent behavior supports selective reduction of target molecules while maintaining physiological levels of essential components.
-
Targeted and selective
Only small and middle-sized molecules—up to approximately 60 kDa — can enter the inner porous structure of the polymer beads. This size selectivity excludes larger plasma proteins such as albumin, coagulation factors, and immunoglobulins from relevant adsorption.
-
Adsorption of hydrophobic substances
Adsorption refers to the attachment of molecules onto a surface through physico-chemical interactions, whereas processes such as dialysis rely on diffusion or convection. Molecules with hydrophobic structural characteristics — such as certain cytokines and antithrombotic agents — can bind to the polymer surface and become captured within the bead’s porous matrix.
-
Biocompatibility
The device materials have been designed to minimize blood cell interaction and complement activation during use.
-
Concentration-Dependent Adsorption
Substances at higher concentrations are preferentially adsorbed by the polymer beads, whereas compounds at lower concentrations are removed more slowly. This concentration-dependent behavior supports selective reduction of target molecules while maintaining physiological levels of essential components.
What bead technology can do
CytoSorbents’ proprietary bead technology provides physicians with an advanced tool for the adsorption of size-selected water-insoluble substances and toxins from whole blood complementing conventional diffusion-based purification techniques.
-
Cytokine imbalance
Massive and uncontrolled production of cytokines — often referred to as a “cytokine storm” — can be triggered, for example, by infection in sepsis. This excessive inflammatory response may have acute, life-threatening consequences due to circulatory shock, capillary leakage, and microcirculatory disturbances, which can lead to multiple organ dysfunction and death.
-
Removal of excessive cytokine levels
Adsorptive reduction of elevated cytokine concentrations is intended to support the re-balancing of inflammatory mediators in the bloodstream. By modulating the systemic inflammatory response, this mechanism is intended to contribute to stabilization of hemodynamic and metabolic parameters in patients with severe inflammation.
-
Bilirubin imbalance
Bilirubin, a breakdown product of hemoglobin, is normally metabolized and excreted by the liver. In liver dysfunction or failure, bilirubin and other substances such as bile acids may accumulate. Elevated levels of these compounds can have harmful effects on hepatic and other cellular functions.
-
Removal of bilirubin
The technology is designed to adsorb bilirubin and other hydrophobic metabolites from whole blood, supporting extracorporeal liver-support therapy.
-
Myoglobin imbalance
A major breakdown of skeletal muscle (rhabdomyolysis) leads to excessive release of the muscle protein myoglobin, which carries the risk of acute kidney injury.
-
Reduction of the myoglobin level
The bead technology is designed for the reduction of myoglobin to support renal replacement therapy.
-
Imbalance caused by antithrombotic agents in the context of surgery
Antithrombotic medications are essential in the management of cardiovascular disease. However, their use can pose a bleeding risk for patients requiring urgent surgical or interventional procedures, particularly when insufficient time is available for natural elimination.
-
Removal of antithrombotic agents
Intraoperative use of our bead technology is intended for the adsorptive removal of selected antithrombotic agents during cardiopulmonary bypass, intended to assist in restoring hemostatic balance.
Additional Information
- Jansen et al., Crit Care 2023; 27(1):117
- Diab et al., Circ 2022; 145(13):959-968
- Scharf et al., Sci Rep 2021; 11(1);10190
- Albrecht et al., Blood Purif 2024; 53(2):88-95
- Hassan et al., JTCVS Open 2023; 15:190-196
- Chen J et al, Regenerative Biomaterials 2017; 4(1):31-37
- Waalders et al., Crit Care Med 2024; 52(4):e152-e153
- Bernardi et al., Crit Care 2016; 20(1):96
- Poli et al., Crit Care 2019; 23:108
- Gleason et al., Sem Thorac Cardiovasc Surg 2019; 31(4):783-793
- David et al., J Int Care 2017; 5:12
- Kogelmann et al., J Clin Med 2024; 13(1):294
- Soltesz et al., J Clin Med 2022; 11(12):6517
- Rugg C et al., Biomedicines 2020; 8(12):539
- Szigetvary et al., Biomed 2023; 11811):3068
- Riva et al., J Artif Orgs 2023; epub
- Grafe et al., Ren Fail 2023; 45(2):2259231
- Hassan et al., Ann Thor Cardiovasc Surg 2022; 28(3):186-192
- Hassan et al., Ann Thorac Surg 2019; 108(1):45-51
CytoSorb 300 IFU 03/2023 – Indications:
CytoSorb is indicated for use in conditions where elevated levels of cytokines and/or bilirubin and/or myoglobin exist. CytoSorb is indicated for use intraoperatively during cardio-pulmonary bypass surgery for the removal of P2Y12-Inhibitor Ticagrelor and/or Factor Xa-Inhibitor Rivaroxaban. Results from current studies suggest that CytoSorb may be administered for up to 7 consecutive days. Maximum Treatment Time per Device: 24 Hour.
What bead technology can do
CytoSorbents’ proprietary bead technology provides physicians with an advanced tool for adsorption of selected water-insoluble and protein-bound molecules that complements conventional dialysis techniques.
Voices around the world
